Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Pfizer Launches Herceptin Biosimilar in Japan
August 23, 2019
- Price Revision Rates in October Re-Pricing Vary in Crowded DPP-4 Class: Survey
August 22, 2019
- Celltrion/Nippon Kayaku Herceptin Biosimilars Get OK for New Breast Cancer Dosing Schedule
August 22, 2019
- GSK’s Daprodustat Reaches 1st NDA Filing, in Japan
August 22, 2019
- NEDO to Subsidize Development of FunPep’s Antibody-Inducing Peptide for Psoriasis Treatment
August 22, 2019
- Tomita Pharmaceutical Invests in Wearable Medical Device Startup
August 22, 2019
- Frontloaded Price Cuts before Regular April Revision Hurts, Say Drug Makers
August 21, 2019
- Teva Takeda to License 10 APIs/20 Products from Sawai as It Plans to Shutter In-House Plants
August 21, 2019
- Big 3 Generic Players Braced for Average 9.2% Price Cut in October Re-Pricing
August 20, 2019
- Tax Hike Re-Pricing Slams Small Pharma and Gx Players, Impact Milder for Big Firms: Survey
August 20, 2019
- Sumitomo Dainippon Flip-Plops on Sales Force Cutback as It Ramps Up Diabetes Push
August 19, 2019
- Pharmacist Average Monthly Salary Down 9,636 Yen: Survey
August 19, 2019
- Osaka Univ. Spinout StemRIM Makes Tepid TSE Debut
August 16, 2019
- Towa Starts Joint Research with National CV Center on Disease Prevention, Healthy Life Expectancy Extension
August 16, 2019
- AstraZeneca Japan Adjusts Company Rules for Same-Sex, Common-Law Couples
August 16, 2019
- Otsuka Rings Up Double-Digit Growth in H1 Pharma Sales
August 9, 2019
- Takeda Seeks Japan Approval for Entyvio SC Form
August 9, 2019
- Ono Seeks Label Expansion for Onoact Sepsis-Associated Tachyarrhythmia
August 9, 2019
- Mitsubishi Tanabe’s Schizophrenia Drug Cariprazine Approved in 2 Asian Nations
August 9, 2019
- Mitsubishi Tanabe Submits PI Study Protocol for Spinal Cord Injury Treatment MT-3921 in US
August 9, 2019
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…